Targeted Oncology6h
Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy
During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of ...
Targeted Oncology6h
SunRISe-2 Study of TAR-200 Plus Cetrelimab in MIBC Discontinues
The SunRISe-2 trial evaluating TAR-200 combined with cetrelimab vs chemoradiation in muscle-invasive bladder cancer has been ...
Targeted Oncology8h
STX-241 Trial Begins for EGFR TKI-Resistant NSCLC Treatment
The first patient in a phase 1/2 trial investigating a novel agent for the treatment of non–small cell lung cancer has been ...
Targeted Oncology10h
VLS-1488 Gains FDA Fast Track Status in Advanced Ovarian Cancer
The FDA has granted VLS-1488 fast track designation in patients with platinum-resistant high-grade serous ovarian cancer.
Targeted Oncology12h
Perioperative Pembrolizumab Betters Survival in Stage III/IV Head and Neck Cancer
The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.
Targeted Oncology13h
Long-Term Data Confirms Cemiplimab Benefits in High PD-L1 NSCLC
Ana Baramidze, MD, PhD, discussed 5-year follow-up results from the EMPOWER-Lung study evaluating cemiplimab vs chemotherapy ...